Loading: 100%
AbbVie Inc. logo
no logo available
General Information
Investor relations pageIR page no data available
Founding year no data available
Headquarter North Chicago, United States of AmericaNorth Chicago, United States of Americano data available
Employees 29,000 (as per Q1 2017)no data available
Sector Drug Manufacturers, HealthcareDrug Manufacturers, Healthcareno data available
Ticker ABBVno data available
Financial year endsFY ends End of Decemberno data available
Stock Information (historical prices adjusted for splits and dividends)
Adj. Closing prices (in USD) -Common sharesNov. 16Jan. 17März 17Mai 17Juli 17Sep. 1750,062,575,087,5100,0
datesClosing price (adj.)
13.10.201790.67
11.10.201791.74
04.10.201789.28
27.09.201784.16
20.09.201786.80
13.09.201787.85
06.09.201776.51
30.08.201773.41
23.08.201771.02
16.08.201769.93
09.08.201771.52
02.08.201770.22
26.07.201772.09
19.07.201772.26
12.07.201771.38
05.07.201771.34
27.06.201771.25
20.06.201770.10
13.06.201768.58
06.06.201766.80
30.05.201764.98
23.05.201764.81
16.05.201765.80
09.05.201765.13
02.05.201765.58
25.04.201764.09
18.04.201762.65
11.04.201763.17
04.04.201763.45
28.03.201764.30
21.03.201763.69
14.03.201764.00
07.03.201762.07
28.02.201760.27
21.02.201760.26
14.02.201759.27
07.02.201759.02
31.01.201759.56
24.01.201759.04
17.01.201760.29
10.01.201761.79
03.01.201760.19
27.12.201660.28
19.12.201660.01
12.12.201659.84
05.12.201658.70
28.11.201657.35
21.11.201658.27
14.11.201660.73
07.11.201656.82
31.10.201653.80
24.10.201658.95
17.10.201658.00
no share price data source found
Share price data requested
Key Figures
Last Closing Price
as per Oct 13, 2017, in USD
90.67n/a
Market Capitalisation
in million USD
144,305n/a
Enterprise Value
in million USD
175,008n/a
Common Shares Outstanding
as per Apr 24, 2017
1,591,540,513n/a
Preferred Shares Outstanding
as per Apr 24, 2017
n/a
Average Basic Shares Outstanding
TTM
1,617,250,000n/a
Average Diluted Shares Outstanding
TTM
1,625,500,000n/a
Index Membership
n/a
Business Summary
AbbVie Inc is a biopharmaceutical company that discovers, develops, manufactures and sells a range of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders.
no data available
Key Financials & Ratios (all figures TTM as per Mar 31, 2017, million USD, full statements further below)
Profit & Loss
Revenues 26,218n/a
Gross Profit 20,138n/a
Operating Income 9,715n/a
EBITDA 11,010n/a
Net Profit 6,310n/a
Balance Sheet
Cash and Cash Equivalents 6,248n/a
Receivables 4,677n/a
Total Current Assets 15,547n/a
PP&E 2,612n/a
Total Assets 65,664n/a
Accounts Payable 0n/a
Current Debt 425n/a
Total Current Liabilities 8,844n/a
Long-Term Debt 36,526n/a
Total Liabilities 60,666n/a
Total Equity 4,998n/a
Cash Flow
Depreciation & Amortisation 1,295n/a
Change in Working Capital -1,954n/a
Operating Cash Flow 7,015n/a
Net Change in PP&E and Intangibles -453n/a
Investing Cash Flow -5,300n/a
Dividends Paid -3,820n/a
Financing Cash Flow -4,503n/a
Total Change in Cash -2,816n/a
Free Cash Flow 6,719n/a
Profitability Ratios
Gross Margin 76.8%n/a
Operating Margin 37.1%n/a
Net Profit Margin 24.1%n/a
Return on Equity 126.3%n/a
Return on Assets 9.6%n/a
Per Share Figures
Basic EPS 3.90n/a
Diluted EPS 3.88n/a
Sales per Share 16.21n/a
Book Value per Share 3.09n/a
FCF per Share 4.15n/a
Dividends per Share 2.36n/a
Price Multiples
Price to Earnings Ratio 23.24n/a
Price to Sales Ratio 5.59n/a
Price to Book Value 29.34n/a
Price to Free Cash Flow 21.82n/a
Valuation Metrics
EV/EBITDA 15.90n/a
EV/Sales 6.68n/a
Book to Market Value 0.03n/a
Other Ratios
Current Ratio 175.8%n/a
Liabilities to Equity Ratio 1,213.8%n/a
Debt to Assets Ratio 56.3%n/a
Profit & Loss StatementP&L data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '11FY '12FY '13FY '14FY '15FY '16
Revenue
17,444
18,380
18,790
19,960
22,859
25,638
Sales & Services Revenue
0
0
0
0
0
0
Financing Revenue
0
0
0
0
0
0
Other Revenue
0
0
0
0
0
0
Cost of revenue
-4,639
-4,508
-4,581
-4,426
-4,500
-5,833
Cost of Goods & Services
0
0
0
0
0
0
Cost of Financing Revenue
0
0
0
0
0
0
Cost of Other Revenue
0
0
0
0
0
0
Gross Profit
12,805
13,872
14,209
15,534
18,359
19,805
Other Operating Income
0
0
0
0
0
0
Operating Expenses
-8,512
-7,767
-8,207
-11,021
-10,672
-10,221
Selling, General & Administrative
-5,894
-4,989
-5,352
-7,724
-6,387
-5,855
Selling & Marketing
0
0
0
0
0
0
General & Administrative
0
0
0
0
0
0
Research & Development
-2,618
-2,778
-2,855
-3,297
-4,285
-4,366
Depreciation & Amortization
0
0
0
0
0
0
Provision For Doubtful Accounts
0
0
0
0
0
0
Other Operating Expense
0
0
0
0
0
0
Operating Income (Loss)
4,293
6,105
6,002
4,513
7,687
9,584
Non-Operating Income (Loss)
48
-92
-332
-1,792
-892
-1,500
Interest Expense, net
20
-84
-278
-391
-686
-965
Interest Expense
0
0
0
0
0
0
Interest Income
0
0
0
0
0
0
Other Investment Income (Loss)
0
0
0
0
0
0
Foreign Exchange Gain (Loss)
30
-17
-55
-678
-193
-303
Income (Loss) from Affiliates
0
0
0
0
0
0
Other Non-Operating Income (Loss)
-2
9
1
-723
-13
-232
Pretax Income (Loss), Adjusted
4,341
6,013
5,670
2,721
6,795
8,084
Abnormal Gains (Losses)
-673
-288
-338
-352
-150
-200
Acquired In-Process R&D
0
0
0
0
0
0
Merger / Acquisition Expense
0
0
0
0
0
0
Abnormal Derivatives
0
0
0
0
0
0
Disposal of Assets
0
0
0
0
0
0
Early extinguishment of Debt
0
0
0
0
0
0
Asset Write-Down
0
0
0
0
0
0
Impairment of Goodwill & Intangibles
0
0
0
0
0
0
Sale of Business
0
0
0
0
0
0
Legal Settlement
0
0
0
0
0
0
Restructuring Charges
0
0
0
0
0
0
Sale of and Unrealized Investments
0
0
0
0
0
0
Insurance Settlement
0
0
0
0
0
0
Other Abnormal Items
0
0
0
0
0
0
Pretax Income (Loss)
3,668
5,725
5,332
2,369
6,645
7,884
Income Tax (Expense) Benefit, net
-235
-450
-1,204
-595
-1,501
-1,931
Current Income Tax
0
0
0
0
0
0
Deferred Income Tax
0
0
0
0
0
0
Tax Allowance/Credit
0
0
0
0
0
0
Income (Loss) from Affiliates, net of taxes
0
0
0
0
0
0
Income (Loss) from Continuing Operations
3,433
5,275
4,128
1,774
5,144
5,953
Net Extraordinary Gains (Losses)
0
0
0
0
0
0
Discontinued Operations
0
0
0
0
0
0
XO & Accounting Charges & Other
0
0
0
0
0
0
Income (Loss) Including Minority Interest
3,433
5,275
4,128
1,774
5,144
5,953
Minority Interest
0
0
0
0
0
0
Net Income
3,433
5,275
4,128
1,774
5,144
5,953
Preferred Dividends
0
0
0
0
0
0
Other Adjustments
0
0
0
0
0
0
Net Income Available to Common Shareholders
3,433
5,275
4,128
1,774
5,144
5,953
Remarks
restated on Feb 21, 2014 n/a
calculated values,
restated on Feb 20, 2015 n/a
calculated values,
restated on Feb 19, 2016 n/a
calculated values,
restated on Feb 17, 2017 n/a
calculated values,
restated on Feb 17, 2017 n/a
calculated values,
restated on Feb 17, 2017 n/a
calculated values,
Balance SheetBS data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '11FY '12FY '13FY '14FY '15FY '16
Assets
Cash, Cash Equivalents & Short Term Investments
n/a
7,976
9,895
8,374
8,407
6,423
Cash & Cash Equivalents
n/a
5,901
9,595
8,348
8,399
5,100
Short Term Investments
n/a
2,075
300
26
8
1,323
Accounts & Notes Receivable
n/a
4,298
3,854
3,735
4,730
4,758
Accounts Receivable, Net
n/a
4,298
3,854
3,735
4,730
4,758
Notes Receivable, Net
n/a
0
0
0
0
0
Unbilled Revenues
n/a
0
0
0
0
0
Inventories
n/a
1,091
1,150
1,124
1,719
1,444
Raw Materials
n/a
0
0
0
0
0
Work In Process
n/a
0
0
0
0
0
Finished Goods
n/a
0
0
0
0
0
Other Inventory
n/a
0
0
0
0
0
Other Short Term Assets
n/a
1,989
2,949
2,848
1,458
3,562
Prepaid Expenses
n/a
1,320
1,234
1,952
1,458
3,562
Derivative & Hedging Assets
n/a
0
0
0
0
0
Assets Held-for-Sale
n/a
0
0
0
0
0
Deferred Tax Assets
n/a
669
766
896
0
0
Income Taxes Receivable
n/a
0
949
0
0
0
Discontinued Operations
n/a
0
0
0
0
0
Miscellaneous Short Term Assets
n/a
0
0
0
0
0
Total Current Assets
n/a
15,354
17,848
16,081
16,314
16,187
Property, Plant & Equipment, Net
n/a
2,247
2,298
2,485
2,565
2,604
Property, Plant & Equipment
n/a
0
0
0
0
0
Accumulated Depreciation
n/a
0
0
0
0
0
Long Term Investments & Receivables
n/a
119
118
92
145
1,783
Long Term Investments
n/a
0
0
0
0
0
Long Term Marketable Securities
n/a
0
0
0
0
0
Long Term Receivables
n/a
0
0
0
0
0
Other Long Term Assets
n/a
9,288
8,934
8,855
34,026
45,525
Intangible Assets
n/a
2,323
1,890
1,513
19,709
28,897
Goodwill
n/a
6,130
6,277
5,862
13,168
15,416
Other Intangible Assets
n/a
0
0
0
0
0
Prepaid Expense
n/a
0
0
0
0
0
Deferred Tax Assets
n/a
0
0
0
0
0
Derivative & Hedging Assets
n/a
0
0
0
0
0
Prepaid Pension Costs
n/a
0
0
0
0
0
Discontinued Operations
n/a
0
0
0
0
0
Investments in Affiliates
n/a
0
0
0
0
0
Miscellaneous Long Term Assets
n/a
835
767
1,480
1,149
1,212
Total Noncurrent Assets
n/a
11,654
11,350
11,432
36,736
49,912
Total Assets
n/a
27,008
29,198
27,513
53,050
66,099
Liabilities and owners' equity
Payables & Accruals
n/a
5,734 5734000000
6,448 6448000000
6,954 6954000000
8,463 8463000000
9,379 9379000000
Accounts Payable
n/a
0 0
0 0
0 0
0 0
0 0
Accrued Taxes
n/a
0 0
0 0
0 0
0 0
0 0
Interest & Dividends Payable
n/a
0 0
0 0
0 0
0 0
0 0
Other Payables & Accruals
n/a
0 0
0 0
0 0
0 0
0 0
Short Term Debt
n/a
1,042 1042000000
431 431000000
4,439 4439000000
2,431 2431000000
402 402000000
Short Term Borrowings
n/a
0 0
0 0
0 0
0 0
0 0
Short Term Capital Leases
n/a
0 0
0 0
0 0
0 0
0 0
Current Portion of Long Term Debt
n/a
0 0
0 0
0 0
0 0
0 0
Other Short Term Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
Deferred Revenue
n/a
0 0
0 0
0 0
0 0
0 0
Derivatives & Hedging
n/a
0 0
0 0
0 0
0 0
0 0
Deferred Tax Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
0 0
0 0
0 0
Miscellaneous Short Term Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
Total Current Liabilities
n/a
6,776 6776000000
6,879 6879000000
11,393 11393000000
10,894 10894000000
9,781 9781000000
Long Term Debt
n/a
14,630 14630000000
14,292 14292000000
10,538 10538000000
29,240 29240000000
36,440 36440000000
Long Term Borrowings
n/a
0 0
0 0
0 0
0 0
0 0
Long Term Capital Leases
n/a
0 0
0 0
0 0
0 0
0 0
Other Long Term Liabilities
n/a
5,952 5952000000
3,535 3535000000
3,840 3840000000
8,971 8971000000
15,242 15242000000
Accrued Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
Pension Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
Pensions
n/a
0 0
0 0
0 0
0 0
0 0
Other Post-Retirement Benefits
n/a
0 0
0 0
0 0
0 0
0 0
Deferred Compensation
n/a
0 0
0 0
0 0
0 0
0 0
Deferred Revenue
n/a
0 0
0 0
0 0
0 0
0 0
Deferred Tax Liabilities
n/a
0 0
0 0
159 159000000
5,276 5276000000
6,890 6890000000
Derivatives & Hedging
n/a
0 0
0 0
0 0
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
0 0
0 0
0 0
Miscellaneous Long Term Liabilities
n/a
5,952 5952000000
3,535 3535000000
3,681 3681000000
3,695 3695000000
8,352 8352000000
Total Noncurrent Liabilities
n/a
20,582 20582000000
17,827 17827000000
14,378 14378000000
38,211 38211000000
51,682 51682000000
Total Liabilities
n/a
27,358 27358000000
24,706 24706000000
25,771 25771000000
49,105 49105000000
61,463 61463000000
Preferred Equity
n/a
0 0
0 0
0 0
0 0
0 0
Share Capital & Additional Paid-In Capital
n/a
0 0
3,687 3687000000
4,210 4210000000
13,097 13097000000
13,696 13696000000
Common Stock
n/a
0 0
0 0
0 0
0 0
0 0
Additional Paid in Capital
n/a
0 0
0 0
0 0
0 0
0 0
Other Share Capital
n/a
0 0
0 0
0 0
0 0
0 0
Treasury Stock
n/a
0 0
-320 -320000000
-972 -972000000
-8,839 -8839000000
-10,852 -10852000000
Retained Earnings
n/a
0 0
1,567 1567000000
535 535000000
2,248 2248000000
4,378 4378000000
Other Equity
n/a
-350 -350000000
-442 -442000000
-2,031 -2031000000
-2,561 -2561000000
-2,586 -2586000000
Equity Before Minority Interest
n/a
-350 -350000000
4,492 4492000000
1,742 1742000000
3,945 3945000000
4,636 4636000000
Minority Interest
n/a
0 0
0 0
0 0
0 0
0 0
Total Equity
n/a
-350 -350000000
4,492 4492000000
1,742 1742000000
3,945 3945000000
4,636 4636000000
Total Liabilities & Equity
n/a
27,008 27008000000
29,198 29198000000
27,513 27513000000
53,050 53050000000
66,099 66099000000
Remarks restated on n/a restated on Feb 21, 2014 n/a restated on Feb 20, 2015 n/a restated on Feb 19, 2016 n/a restated on Feb 17, 2017 n/a restated on May 5, 2017 n/a
Cash Flow StatementCF data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '11FY '12FY '13FY '14FY '15FY '16
Net Income/Starting Line
3,433
5,275
4,128
1,774
5,144
5,953
Net Income
0
0
0
0
0
0
Net Income From Discontinued Operations
0
0
0
0
0
0
Other Adjustments
0
0
0
0
0
0
Depreciation & Amortization
1,272
1,150
897
786
836
1,189
Non-Cash Items
836
541
584
1,777
1,051
1,588
Stock-Based Compensation
0
0
0
0
0
0
Deferred Income Taxes
0
0
0
0
0
0
Other Non-Cash Adjustments
0
0
0
0
0
0
Change in Working Capital
706
-621
658
-788
504
-1,689
(Increase) Decrease in Accounts Receivable
0
0
0
0
0
0
(Increase) Decrease in Inventories
0
0
0
0
0
0
Increase (Decrease) in Accounts Payable
0
0
0
0
0
0
Increase (Decrease) in Other
0
0
0
0
0
0
Net Cash From Discontinued Operations (operating)
0
0
0
0
0
0
Cash from Operating Activities
6,247
6,345
6,267
3,549
7,535
7,041
Change in Fixed Assets & Intangibles
-356
-333
-491
-612
-532
-479
Disposition of Fixed Assets & Intangibles
0
0
0
0
0
0
Disposition of Fixed Assets
0
0
0
0
0
0
Disposition of Intangible Assets
0
0
0
0
0
0
Acquisition of Fixed Assets & Intangibles
0
0
0
0
0
0
Purchase of Fixed Assets
0
0
0
0
0
0
Acquisition of Intangible Assets
0
0
0
0
0
0
Other Change in Fixed Assets & Intangibles
0
0
0
0
0
0
Net Change in Long Term Investment
-688
-1,397
1,775
308
48
-2,956
Decrease in Long Term Investment
0
0
0
0
0
0
Increase in Long Term Investment
0
0
0
0
0
0
Net Cash From Acquisitions & Divestitures
-273
-688
0
0
-11,488
-2,495
Net Cash from Divestitures
0
0
0
0
0
0
Cash for Acqusition of Subsidiaries
0
0
0
0
0
0
Cash for Joint Ventures
0
0
0
0
0
0
Net Cash from Other Acquisitions
0
0
0
0
0
0
Other Investing Activities
1,870
0
-405
-622
-964
-144
Net Cash From Discontinued Operations (investing)
0
0
0
0
0
0
Cash from Investing Activities
553
-2,418
879
-926
-12,936
-6,074
Dividends Paid
0
0
-2,555
-2,661
-3,294
-3,717
Cash From (Repayment of) Debt
0
15,586
-601
-5
16,623
5,588
Cash From (Repayment of) Short Term Debt, net
0
0
0
0
0
0
Cash From (Repayment of) Long Term Debt, net
0
0
0
0
0
0
Repayments of Long Term Debt
0
0
0
0
0
0
Cash From Long Term Debt
0
0
0
0
0
0
Cash From (Repurchase of) Equity
0
0
27
-433
-7,431
-5,765
Increase in Capital Stock
0
0
0
0
0
0
Decrease in Capital Stock
0
0
0
0
0
0
Other Financing Activities
-6,783
-13,655
-313
-194
-146
-34
Net Cash From Discontinued Operations (financing)
0
0
0
0
0
0
Cash from Financing Activities
-6,783
1,931
-3,442
-3,293
5,752
-3,928
Net Cash Before Disc. Operations and FX
17
5,858
3,704
-670
351
-2,961
Change in Cash from Disc. Operations and Other
0
0
0
0
0
0
Net Cash Before FX
17
5,858
3,704
-670
351
-2,961
Effect of Foreign Exchange Rates
0
16
-10
-577
-300
-338
Net Changes in Cash
17
5,874
3,694
-1,247
51
-3,299
Remarks
restated on Feb 21, 2014 n/a
calculated values,
restated on Feb 20, 2015 n/a
calculated values,
restated on Feb 19, 2016 n/a
calculated values,
restated on Feb 17, 2017 n/a
calculated values,
restated on Feb 17, 2017 n/a
calculated values,
restated on Feb 17, 2017 n/a
calculated values,
Some of the data shown on this page is provided for free by IEX
Sumo